Understanding the costs of care for cystic fibrosis: an analysis by age and severity. CHERE Working Paper 2011/1
AbstractCystic fibrosis (CF) is the most common life-shortening genetic disease, with an incidence of 1 in 2500 and carrier frequency of 1 in 25, amongst Caucasians (Welsh, Ramsey et al. 2001). With recent advances in treatment, most children with CF now can expect to survive into adulthood and life expectancy has improved considerably. CF is a progressive disease which affects many organ systems and as the disease progresses patients require more intensive health care that includes home based care and medications, along with more frequent and prolonged hospital admissions, and in around half of all cases lung transplantation.(Jason, Leah et al. 2009; Paul, Leah et al. 2009). As new and improving treatment options become available, the pattern of care will change, which will impact on the costs of treatment and on patient outcomes. For example, two of the key medications developed in the last 15 years, Pulmozyme and TOBI (not licensed for use in Australia) cost A$14,000 pa; and more sophisticated technology, such as gene-based treatments will be equally, or more expensive. Thus health care policy makers and funders will expect rigorous assessments of the cost-effectiveness of new treatments.
Download InfoIf you experience problems downloading a file, check if you have the proper application to view it first. In case of further problems read the IDEAS help page. Note that these files are not on the IDEAS site. Please be patient as the files may be large.
Bibliographic InfoPaper provided by CHERE, University of Technology, Sydney in its series Working Papers with number 2011/1.
Date of creation: Mar 2011
Date of revision:
Cystic Fibrosis; costs; cost effectiveness;
Find related papers by JEL classification:
- I19 - Health, Education, and Welfare - - Health - - - Other
This paper has been announced in the following NEP Reports:
You can help add them by filling out this form.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Liz Chinchen).
If references are entirely missing, you can add them using this form.